Area of research
Oncology · Molecular Biology
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Glycosylation and Glycoproteins Research, Cancer Cells and Metastasis, and Pancreatic function and diabetes.
RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer.
Targeting the DDX3/PAF1 axis enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma
Unveiling the gut-pancreas axis: microbial influence on stemness and tumor microenvironment of PDAC.
A timeless chronicle: Effects of cigarette smoke on GPR15 receptor and its oncogenic potential.
Sugar symphony: glycosylation in cancer metabolism and stemness.
Radiation Promotes Acute and Chronic Damage to Adipose Tissue.
PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer
Contract to kill: GNAS mutation.
ProteotoxomiRs: Diagnostic and pathologic miRNA signatures for reductive stress induced proteotoxic heart disease.
Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer.
Emerging pathways yielding opportunities for future treatments in pancreatic ductal adenocarcinoma.
Emerging Trends in Gastrointestinal Cancer Targeted Therapies: Harnessing Tumor Microenvironment, Immune Factors, and Metabolomics Insights.
Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LAMA5/ITGA4 Axis.
Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma.
Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal Adenocarcinoma
Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal adenocarcinoma.
PAF1/HIF1α axis rewires the glycolytic metabolism to fuel aggressiveness of pancreatic cancer.
MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR.
Metabolic Rewiring and Stemness: A Critical Attribute of Pancreatic Cancer Progression.
Chimeric antibody targeting unique epitope on onco-mucin16 reduces tumor burden in pancreatic and lung malignancies.
Elevated PAF1-RAD52 axis confers chemoresistance to human cancers.
MUC16 and TP53 family co-regulate tumor-stromal heterogeneity in pancreatic adenocarcinoma.
Clinical and Molecular Attributes and Evaluation of Pancreatic Cystic Neoplasm.
Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis.
Reduction in O-glycome induces differentially glycosylated CD44 to promote stemness and metastasis in pancreatic cancer.
Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling.
MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion.
Acinar to ductal cell trans-differentiation: A prelude to dysplasia and pancreatic ductal adenocarcinoma.
Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma.
Chemokine-mucinome interplay in shaping the heterogeneous tumor microenvironment of pancreatic cancer.